Diaceutics (LON:DXRX) Sets New 12-Month High - Still a Buy?

Key Points

• Diaceutics PLC shares reached a new 52-week high at GBX 151.50 ($2.05), closing at GBX 150 ($2.03) with over 1 million shares traded.
• Market analysts show a mixed outlook with Royal Bank Of Canada lowering its price target to GBX 185, while Canaccord Genuity maintains a buy rating with a target of GBX 180.
• The company boasts a significant market cap of £126.82 million and a current ratio of 4.85, indicating a strong financial position.

Diaceutics PLC (LON:DXRX - Get Free Report)'s share price hit a new 52-week high during trading on Friday . The stock traded as high as GBX 151.50 ($2.05) and last traded at GBX 150 ($2.03), with a volume of 1011205 shares trading hands. The stock had previously closed at GBX 147 ($1.99).

Analyst Upgrades and Downgrades

Several brokerages have commented on DXRX. Canaccord Genuity Group reiterated a "buy" rating and issued a GBX 180 price target on shares of Diaceutics in a research note on Tuesday, July 22nd. Royal Bank Of Canada lowered their target price on shares of Diaceutics from GBX 195 to GBX 185 and set an "outperform" rating on the stock in a research report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of GBX 175.

Diaceutics Trading Up 1.3%

The company has a debt-to-equity ratio of 0.39, a current ratio of 4.85 and a quick ratio of 9.92. The firm has a market capitalization of £128.51 million, a PE ratio of -7,524.75 and a beta of 0.58. The business's 50-day moving average price is GBX 137.39 and its 200-day moving average price is GBX 127.74.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.